ºÝºÝߣ

multiple sclerosis disease modifying treatment progressive multiple sclerosis neurology cladribine ms natalizumab equity primary progressive multiple sclerosis venoplasty treatment ccsvi off-label health economics social media time matters health scam #ectrims2016 spms disease progression ppms pml tysabri laquinimod arpeggio disease multiple sclerosis therapy neda neuroscience lower and middle income countries nhs neuroanatomy #chariotms #thinkhand upper limb function access to treatment b cells fingolimod rebound disease mri neuronal loss cerebral cortex spinal cord synapses axonal loss neuropathology post mortem immune therapy side effects adverse effects trials